Artificial Intelligence Is Expanding Into Neurological Research
Artificial intelligence is opening new possibilities in medical research, particularly in fields that require researchers to interpret complex biological signals.
From sleep diagnostics to neurological monitoring, scientists are exploring how AI and advanced sensing technologies could help clinicians better understand changes occurring inside the human body.
One area of interest involves developing technologies that can collect useful neurological information without relying exclusively on invasive procedures.
On October 23, 2026, South Korean sleep medicine AI company HoneyNaps announced its selection for a Eurostars international research and development project focused on non-invasive neurological monitoring.
The initiative brings together researchers and technology organizations from South Korea and Sweden to develop and evaluate a platform combining electromagnetic sensors, artificial intelligence, and sleep-related biological signals.
The project is an early-stage research and development effort rather than an announcement of an approved clinical product.
An International Collaboration Connecting AI, Engineering, and Medicine
The project, titled Development of a Spectroscopic Electromagnetic Sensing and Artificial Intelligence Platform for Non-Invasive Neurological Monitoring, includes HoneyNaps and four research and technology partners:
- Yonsei University, South Korea
- Dankook University, South Korea
- Uppsala University, Sweden
- Xantage AB, Sweden
The consortium intends to combine expertise in sensor engineering, artificial intelligence, biological signal analysis, and clinical technology.
Its research will focus on estimating changes in intracranial pressure while analyzing sleep-related physiological information.
Intracranial pressure refers to pressure inside the skull. Monitoring it can be important in certain neurological conditions, but established direct measurement techniques may require invasive procedures.
The researchers aim to investigate whether non-invasive electromagnetic sensing and AI could provide useful estimates of pressure changes.
Their proposed platform will combine miniature sensing components, wireless biological signal collection, and algorithms designed to interpret complex physiological data.
The project targets Technology Readiness Level 6, which generally involves demonstrating technology in a relevant environment rather than establishing routine clinical availability.
How AI and Sleep Data Could Support Neurological Monitoring
HoneyNaps’ contribution focuses on the wireless collection and analysis of biological signals associated with sleep.
These include:
- Electroencephalogram (EEG) measurements of electrical brain activity
- Electrooculogram (EOG) measurements of eye movements
- Electromyogram (EMG) measurements of muscle activity
- Electrocardiogram (ECG) measurements of heart activity
- Blood oxygen saturation and respiratory signals
These measurements are commonly associated with polysomnography, a clinical technique used to study sleep and related physiological activity.
The research team plans to investigate how these signals can be combined with electromagnetic sensor information and AI-based analysis.
The objective is to develop a system capable of estimating intracranial pressure changes and automatically analyzing sleep stages and events.
If successfully developed and validated, the technology could contribute to research on more convenient neurological monitoring.
However, the proposed system’s accuracy, clinical usefulness, and regulatory suitability remain to be established.
Women Behind the Innovation: Christine Kwon and HoneyNaps’ U.S. Presence
International scientific innovation involves more than researchers and engineers.
Technology companies also rely on professionals who help coordinate business activities, communicate developments, and connect organizations across markets.
Christine Kwon is identified as Managing Director of HoneyNaps USA, the company’s U.S. organization based in Cambridge, Massachusetts.
HoneyNaps lists Kwon as its company contact in the October 2026 announcement describing the Eurostars research collaboration.
Her named leadership position provides a relevant example of a woman working within the organizational ecosystem surrounding international AI and healthcare innovation.
The announcement does not specify her responsibilities within the research consortium, and it does not identify her as a principal investigator, inventor, or technical project leader.
Nevertheless, the presence of named women in management roles is relevant to understanding the range of professional pathways associated with technology companies.
Research organizations and healthcare technology businesses require expertise across scientific development, operations, partnerships, communications, regulatory planning, and international business.
These functions can help emerging technologies progress from research initiatives toward potential real-world applications.
Kwon’s role also presents an opportunity to explore the experiences of women working in international healthcare technology organizations.
As HoneyNaps continues developing its U.S. presence, her perspective could provide insight into the business and organizational challenges involved in supporting cross-border innovation.
Building on Existing AI Sleep Technology
HoneyNaps has previously developed AI-powered software for analyzing sleep-study data.
Its SOMNUM platform uses artificial intelligence to assist with the interpretation of physiological recordings collected during sleep studies.
The company announced U.S. Food and Drug Administration clearance for SOMNUM V3.0 in July 2026.
That clearance relates to the company’s existing sleep-analysis software.
It should not be confused with the new neurological monitoring platform proposed through the Eurostars project.
The research consortium intends to develop and validate the new technology and prepare technical documentation relevant to potential future regulatory submissions under the European Union’s medical device framework.
Regulatory preparation does not establish that a device has been approved or is available for clinical use.
What Is the Eurostars Program?
Eurostars is an international research and development funding program operated through the Eureka Network.
The program supports collaborative innovation projects involving businesses and research partners across participating countries.
Its purpose is to encourage the development of technologies with potential commercial applications.
HoneyNaps says its selection is supported in South Korea by the Ministry of Trade, Industry and Resources and the Korea Institute for Advancement of Technology.
The company has not disclosed a specific funding amount associated with its participation.
The project demonstrates how international funding and research programs can bring together institutions with complementary expertise.
Career Opportunities at the Intersection of AI and Biomedical Research
The HoneyNaps collaboration highlights the increasingly interdisciplinary nature of healthcare technology.
Biomedical engineers develop devices and systems that interact with biological processes.
Electrical engineers contribute expertise in sensors, signal acquisition, and wireless technologies.
Machine learning researchers investigate how algorithms can interpret complex datasets.
Neuroscientists study brain function and neurological conditions.
Clinical researchers evaluate whether emerging technologies are safe, reliable, and useful in medical settings.
Technology executives and business development professionals help organizations navigate partnerships, international expansion, and commercialization strategies.
For women pursuing careers in STEM, these intersections provide opportunities to contribute through research, engineering, product development, and organizational leadership.
The project also demonstrates that meaningful contributions to innovation can take different forms, from scientific discovery to building the organizations that support it.
Looking Ahead
The HoneyNaps consortium plans to develop and validate its proposed monitoring platform through staged research.
Its longer-term impact will depend on the reliability of the sensing technology, the performance of its AI models, clinical evidence, and applicable regulatory requirements.
The announcement does not establish when the proposed system might become commercially or clinically available.
For the digital health industry, the collaboration highlights continued interest in combining artificial intelligence with advanced biomedical sensing.
For women in STEM, it illustrates the diverse scientific, technical, and leadership roles involved in international healthcare innovation.
Sources & Further Reading
- HoneyNaps — October 23, 2026 Eurostars Research Announcement
- HoneyNaps — Official Website
- HoneyNaps — July 2026 SOMNUM FDA Clearance Announcement
- FDA — SOMNUM Device Documentation
Discover more from Fems in STEM
Subscribe to get the latest posts sent to your email.
